Talacotuzumab (JNJ-56022473)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Talacotuzumab (JNJ-56022473), covering 2019-02-28 to 2019-02-28. Get the full timeline:
Most recent: Clinical Trial Update: An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy [Phase 2, Phase 3]